Medicines

ARPA-H VITAL-H healthspan drug trial

UT Health San Antonio / ARPA-H PROSPR

If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.

WHAT IT IS TRYING TO CHANGE

What the project is doing

ARPA-H VITAL-H healthspan drug trial is being developed as part of the wider effort to prevent, delay or repair age-related decline.

If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.

The next major checkpoint is the study result and any regulatory submission.

A late study can still fail, reveal safety problems or show a benefit too small to justify approval or cost.

WHERE IT STANDS

ARPA-H VITAL-H healthspan drug trial is being developed as part of the wider effort to prevent, delay or repair age-related decline.

Likely path

Roughly 2–5 years to broader access if the study succeeds and regulators agree.

Why this estimate

Late-stage projects are closer, but failure or delay is still possible.

Record checked: 2026-08-27

ORIGINAL EVIDENCE

The sources below support the project record. RejuvAccess separately checks whether a practical route is open and worth pursuing.

MAKE IT PERSONAL

Ask RejuvAccess to check the evidence, access route, cost and next step for you.